Narcolepsy Drugs Market Analysis

Disease Type (Extreme Sleepiness, Cataplexia)

Based on disease type, the market for narcolepsy drugs is segmented into extreme sleepiness, cataplexia, and others, out of which, extreme sleepiness is estimated to witness the highest market share owing to rising cases of narcolepsy worldwide along with the other disorders. During the projection period, the daytime extreme sleepiness segment is expected to hold the highest share of the market in the entire narcolepsy drugs market. The growth in narcolepsy prevalence increases the incidence of indications and other sleep disorders. Many patients with narcolepsy and other sleep disorders are more likely to experience this symptom, boosting the need for narcolepsy medicines. As additional firms enter the narcolepsy medicines industry, growth will be accelerated.

Therapeutics Type (Central Nervous System Stimulants, Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitor, Sodium Oxybate)

The global market of narcolepsy drugs is also segmented and analyzed for demand and supply by application into Central Nervous System Stimulants, tricyclic antidepressants, selective serotonin reuptake inhibitors, sodium oxybate, and others. Amongst these three segments, the central nervous system stimulants segment is expected to garner a significant share of around ~35% in the year 2035. During the projected period, the Central Nervous System Stimulants segment is anticipated to take over the market. Therapeutics including modafinil, armodafinil, and additional central nerve stimulants for narcolepsy are focused on enhancing wakefulness in individuals with narcolepsy, based to an article published in CNS Drugs named "Recently Approved and Upcoming Treatments for Narcolepsy" in January 2021.

End-user (Retail Pharmacies, Drug Stores, E-Commerce)

Increasing studies about central nervous system stimulants is likely to fuel segment growth. Harmony Biosciences Holdings, Inc., a drug manufacturer devoted to creating and advertising cutting-edge treatments for individuals with rare neurological conditions, released an assessment of data of CNS drugs in December 2021 that assessed the period before the onset of response to pitolisant for EDS and cataplexy in grown-up patients with narcolepsy. Such research is projected to lead to the creation of innovative central nervous system stimulants, propelling the expansion of this segment. 

Our in-depth analysis of the global market includes the following segments: